Table 1 Baseline characteristics of subjects by treatment assignment
From: Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
Esomeprazole (n = 9) | Placebo (n = 8) | p value | |
|---|---|---|---|
Reflux present on pH probe | 5/8 (62%) | 3/5 (60%) | 0.42 |
Male (%) | 67 | 75 | 0.38 |
Pseudomonas present (%) | 89 | 62 | |
MRSA present(%) | 0 | 25 | |
Mean + SD | Mean + SD | ||
Age (years) | 35.72 + 9.6 | 32.81 + 5.84 | 0.41 |
BMI | 24.25 + 4.72 | 21.84 + 3.02 | 0.21 |
# exacerbations past 2 years | 4 + 0 (0) | 5.5 + 1.4 (SD) | |
FEV1 (%) | 58 + 19 | 46 + 21 | 0.14 |
FVC (%) | 74 + 20 | 71 + 16 | 0.88 |
FEV1/FVC | 0.63 + 0.10 | 0.56 + 0.15 | 0.26 |
GSAS distress score | 0.99 + 0.61 | 0.88 + 1.03 | 0.28 |
CFR-QOL score | 72.28 + 10.32 | 77.85 + 18.86 | 0.34 |